List view / Grid view
22 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has launched an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline...
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
25 January 2016 | By Victoria White
The Apollo Therapeutics Fund will support the translation of ground-breaking academic science into innovative new medicines for a broad range of diseases...
11 January 2016 | By Victoria White
mRNA-based therapies are an innovative treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases...
11 December 2015 | By Victoria White
The companies have joined WCPR to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome...
27 November 2015 | By
Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas...
20 November 2015 | By Victoria White
The company has announced three new partnerships that will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids...
20 November 2015 | By Victoria White
The compound exchange represents a novel, open innovation model of collaboration between the two companies.
The large family of pharmaceutical targets represented by G-protein coupled receptors (GPCRs) are usually involved in a number of intracellular effector pathways, leading to many cellular outcomes. In recent years it has been uncovered that different ligands of a given GPCR may engage the pathways selectively, in that ligands that…
17 August 2015 | By Victoria White
Researchers from have identified the molecular mechanism that an adhesion protein of H. pylori uses to attach to stomach ulcers...
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...
3 August 2015 | By Victoria White
AstraZeneca and Isis Pharmaceuticals are to collaborate to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases...
9 July 2015 | By Victoria White
AstraZeneca and EvoRx have successfully completed a one-year research collaboration using EvoRx's Evo-Link technology to discover cell penetrating peptides...
17 June 2015 | By Victoria White
AstraZeneca is to collaborate with Inserm to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD)...
1 June 2015 | By Victoria White
AstraZeneca and Lilly have entered into a clinical trial collaboration to evaluate MEDI4736 in combination with ramucirumab in advanced solid tumours...
